Physician profile
Scott Itzkowitz
NPI 1548240229
$1,371.52
in general payments reported to CMS, 2019-2025
23 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.97 · 2022: $192 · 2023: $175 · 2024: $605 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $194.56 | 2021-2023 | Compliance Endokit |
| Madrigal Pharmaceuticals | $181.13 | 2025 | Rezdiffra |
| Abbvie INC. | $153.45 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.48 | 2024-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $69.60 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $66.71 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $57.65 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $55.38 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.89 | 2022-2023 | Xifaxan |
| Pfizer INC. | $38.58 | 2022-2024 | |
| Corcept Therapeutics | $38.21 | 2024 | Korlym |
| Qol Medical, LLC | $37.64 | 2024 | Sucraid |
| Janssen Biotech, INC. | $31.77 | 2024 | Stelara, Tremfya, Simponi |
| Daiichi Sankyo INC. | $30.16 | 2022-2023 | Injectafer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.51 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $23.52 | 2022 | |
| Dexcom, INC. | $21.46 | 2024 | Dexcom G6 Transmitter |
| Celgene Corporation | $19.70 | 2024 | Zeposia |
| Medtronic, INC. | $18.88 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.23 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $12.74 | 2023 | Linzess |
| Micro-Tech Endoscopy USA, INC. | $9.27 | 2024 | Lockado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Itzkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.